Rankings 2024

February 22, 2024

Legal 500 has once again ranked several partners of TIMES Attorneys as Leading Individuals in Sports Law (Stephan Netzle and Olivier Ducrey) and Intellectual Property (Andrea Mondini). The outstanding work of Markus Kaiser (“pragmatic” and “brilliant”) and Michael Noth (“intuitive and strategic”) was also recognized. Furthermore, TIMES Attorneys is ranked Gold for trademark enforcement and litigation by the World Trademark Review (WTR 1000). Michael Noth and Andrea Mondini are honored with Gold, Markus Kaiser with Silver.

Simone Huser is new partner at TIMES Attorneys

January 9, 2024

We are delighted to announce the appointment of Simone Huser as a new partner of TIMES Attorneys.

Simone Huser has been practicing as an attorney at TIMES Attorneys since 2016. Previously, she worked in two established Swiss law firms and at the Commercial Court of the Canton of Bern. She gained further experience as a lawyer at the Federal Office of Culture. Simone Huser advises and represents clients in proceedings before authorities, courts and arbitral tribunals, in particular in intellectual property and competition law, namely in trademark, copyright, design and unfair competition law. Her practice includes the worldwide filing of trademarks and designs. Her further areas of specialization cover advertising law, media law, data protection law and art law.

The appointment of Simone Huser as a partner of TIMES Attorneys is a great enrichment for our firm and we look forward to continuing to advise and represent our clients at the highest level in partnership with Simone Huser.

TIMES Attorneys won before the Swiss Federal Supreme Court

October 24, 2023

TIMES Attorneys (Andrea Mondini) successfully represented Mepha Pharma AG (the Swiss subsidiary of Teva Pharmaceuticals) in patent infringement proceedings against Novartis regarding a generic version of Novartis’ product Jadenu® (deferasirox).
On appeal, the Swiss Federal Supreme Court affirmed the Swiss Federal Patent Court’s judgment holding that Deferasirox Mepha does not infringe Novartis’ patents. This is a landmark case under Swiss law on the issue of equivalent infringement of numerical ranges.
The judgment is published on: http://www.bger.ch/ext/eurospider/live/de/php/aza/http/index.php?highlight_docid=aza://25-09-2023-4A_273-2023&lang=de&zoom=&type=show_document